劲方医药-B计划全球发售7760万股H股 预计9月19日上市

Core Viewpoint - Jinfang Pharmaceutical-B plans to globally offer 77.6 million H-shares, with approximately 10% allocated for public offering in Hong Kong and 90% for international offering, at a price of HKD 20.39 per share, expected to be listed on September 19, 2025 [1] Group 1: Company Overview - Jinfang Pharmaceutical is an innovative drug development company with a global vision and operational capability, having one innovative drug already approved [1] - The company's vision is to become a globally competitive biopharmaceutical company [1] Group 2: Product Pipeline - The company has established a pipeline consisting of eight candidate products, with five currently in clinical development [1] - One of the core products, GFH925 (Dabert), has been approved in China for the treatment of advanced non-small cell lung cancer (NSCLC) [1] - The company is also exploring therapies for autoimmune diseases, inflammatory diseases, and cancer-related conditions [1] Group 3: Fundraising and Use of Proceeds - The net proceeds from the global offering are expected to be approximately HKD 1.4436 billion [1] - About 71% of the proceeds will be used for the further development of core products GFH925 and GFH375 [1] - Approximately 19% will be allocated for the development of other candidate products, including GFH312 [1] - About 10% will be used for working capital and general corporate purposes [1] Group 4: Strategic Partnerships - The company has signed agreements with several cornerstone investors, including RTW Fund, TruMed, UBS Asset Management, Huatai PineBridge Fund, CITIC Securities International Capital Management, and Qingchi entities [1]